GlassScriptPhysician profile
Jillian Coffey
NPI 1396197463
$6,182.56
in general payments reported to CMS, 2019-2025
19 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,126 · 2022: $1,444 · 2023: $985 · 2024: $1,138 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,612.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,033.19 | 2021-2025 | |
| Boston Scientific Corporation | $701.89 | 2022-2025 | General - Therapies, Baylis Medical Company Radiofrequency Puncture Generator, Watchman |
| Astrazeneca Pharmaceuticals LP | $458.49 | 2021-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $329.36 | 2022-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $286.87 | 2022-2025 | Amvuttra, Onpattro |
| Novartis Pharmaceuticals Corporation | $263.51 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $221.49 | 2021-2025 | Lifevest |
| Abbott Laboratories | $149.25 | 2024-2025 | Navitor, Cardiomems |
| Janssen Pharmaceuticals, INC | $141.10 | 2021-2023 | Xarelto |
| Amgen INC. | $120.51 | 2021-2022 | |
| Pfizer INC. | $110.86 | 2021-2024 | |
| Esperion Therapeutics, INC. | $102.79 | 2021-2022 | |
| Abiomed | $92.81 | 2021-2025 | Impella |
| Merck Sharp & Dohme LLC | $80.12 | 2021-2022 | |
| Cardiva Medical, INC. | $26.33 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.09 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $15.59 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $13.74 | 2023 | |
| Bridgebio Pharma, INC. | $13.57 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Coffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.